Scopus BioPharma (SCPS) Competitors $0.0003 0.00 (0.00%) As of 03/27/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrendsBuy This Stock SCPS vs. SMFL, VAXX, NAVB, EVLO, CMRA, GNCAQ, GNCA, ARDS, STAB, and CALAShould you be buying Scopus BioPharma stock or one of its competitors? The main competitors of Scopus BioPharma include Smart for Life (SMFL), Vaxxinity (VAXX), Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), and Calithera Biosciences (CALA). These companies are all part of the "pharmaceutical products" industry. Scopus BioPharma vs. Smart for Life Vaxxinity Navidea Biopharmaceuticals Evelo Biosciences Comera Life Sciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Statera Biopharma Calithera Biosciences Smart for Life (NASDAQ:SMFL) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability, community ranking and analyst recommendations. Is SMFL or SCPS more profitable? Company Net Margins Return on Equity Return on Assets Smart for LifeN/A N/A N/A Scopus BioPharma N/A N/A N/A Does the MarketBeat Community favor SMFL or SCPS? Scopus BioPharma received 1 more outperform votes than Smart for Life when rated by MarketBeat users. CompanyUnderperformOutperformSmart for LifeOutperform Votes1100.00% Underperform VotesNo VotesScopus BioPharmaOutperform Votes2100.00% Underperform VotesNo Votes Which has preferable valuation & earnings, SMFL or SCPS? Scopus BioPharma has lower revenue, but higher earnings than Smart for Life. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSmart for Life$11.11M0.00-$22.68MN/AN/AScopus BioPharmaN/AN/A-$11.61MN/AN/A Do institutionals & insiders believe in SMFL or SCPS? 28.4% of Smart for Life shares are held by institutional investors. 31.7% of Smart for Life shares are held by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, SMFL or SCPS? Smart for Life has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.22, suggesting that its stock price is 122% less volatile than the S&P 500. Does the media prefer SMFL or SCPS? In the previous week, Smart for Life and Smart for Life both had 1 articles in the media. Smart for Life's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smart for Life 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Scopus BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummarySmart for Life beats Scopus BioPharma on 4 of the 6 factors compared between the two stocks. Remove Ads Get Scopus BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SCPS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCPS vs. The Competition Export to ExcelMetricScopus BioPharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13,000.00$6.92B$5.65B$8.06BDividend YieldN/A2.72%4.57%4.01%P/E RatioN/A7.2023.1419.03Price / SalesN/A226.01385.7893.17Price / CashN/A65.6738.1634.64Price / BookN/A6.476.934.33Net Income-$11.61M$141.90M$3.20B$247.06M7 Day PerformanceN/A-3.20%-2.30%-0.37%1 Month PerformanceN/A-5.64%2.86%-3.85%1 Year PerformanceN/A-7.47%10.66%1.27% Scopus BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCPSScopus BioPharmaN/A$0.00flatN/A-87.5%$13,000.00N/A0.009SMFLSmart for LifeN/A$0.01flatN/A-99.9%$47,000.00$11.11M0.00110VAXXVaxxinityN/A$0.00-99.8%N/A-94.9%$13,000.00N/A0.0090Gap DownNAVBNavidea BiopharmaceuticalsN/A$0.00-50.0%N/A-98.9%$10,000.00$8,126.000.0010Gap DownEVLOEvelo BiosciencesN/A$0.00flatN/A-98.9%$9,000.00N/A0.00120CMRAComera Life SciencesN/A$0.00flatN/A-99.4%$6,000.00$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00N/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastNews CoverageARDSAridis PharmaceuticalsN/A$0.00flatN/A-99.9%$5,000.00$3.09M0.0030STABStatera BiopharmaN/A$0.00flatN/A-83.3%$5,000.00N/A0.0020CALACalithera BiosciencesN/A$0.00flatN/AN/A$3,000.00N/A0.0060 Remove Ads Related Companies and Tools Related Companies Smart for Life Competitors Vaxxinity Competitors Navidea Biopharmaceuticals Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Statera Biopharma Competitors Calithera Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCPS) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for May 7th. Because on that day, I believe we could see a $2 Trillion shock INTO the ma...Timothy Sykes | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scopus BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scopus BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SCPS Stock Free SCPS Stock Alerts